1Kamihira S, Yamada Y. Soluble Fas (APO-1/CD95) isoform in adult T-cell leukemia. Leuk Lymphoma, 2001, 41 (1-2): 169-176.
2Mouawad R, Khayat D, Soubrane C. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an in hibitor of apoptosis, inadvanced melanoma. Melanoma Res, 2000, 10(5):461-467.
3Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med, 2000,78(6):312-325.
4Kase H, Aoki Y, Tanaka K. Fas ligand expression in cervical adenocarcinoma: relevance to lymph node metastasis and tumor progression. Gynecol Oncol, 2003, 90(1 ):70-74.
5Reesink-Peters N, Hougardy BM, van den Heuvel FA,et al.Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol, 2005 , 96(3):705-713.
6Das H, Koizumi T, Sugimoto T, et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer, 2000,82(10):1682-1688.
7Dybikowska A, Sliwinski W, Emerich J,et al. Evaluation of Fas genepromoter polymorphism in cervical cancer patients. Int J Mol Med,2004,14(3):475-478.
8Lai HC, Sytwu HK, Sun CA,et al.Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer,2004,112(6): 1084-1085.
9Park IC, Woo SH, Park MJ,et al.Ionizing radiation and nitric oxide donor sensitize Fas-induced apoptosis via up-regulation of Fas in human cervical cancer cells. Oncol Rep, 2003 , 10(3):629-633.
10Toyozumi Y, Arima N, Izumaru S, et al. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells. Int J Oncol,2004.25(3):721-728.
